Elevated JNK activation contributes to the pathogenesis of human brain tumors

The ERK pathway is typically associated with activation of the EGF receptor and has been shown to play a major role in promoting several tumor phenotypes. An analogous signaling module, the JNK pathway, has not been shown to be consistently activated by the EGF receptor but is instead more uniformly stimulated by cellular stresses and cytokines. The function of the JNK pathway in primary tumors is unclear as it has been implicated in both promoting apoptosis and cell growth in vitro, which may be a reflection of the cell lines chosen. Primary human brain tumors frequently show overexpression of the EGF receptor. To clarify the role of JNK in tumorigenesis, we have investigated the role of JNK in a large panel of primary human brain tumors and tumor derived cell lines. Here we present evidence that JNK has a major role in promoting tumorigenesis both in vivo and in vitro. Western blot analysis demonstrated that 86% (18 of 21) of primary brain tumors showed evidence of JNK activation but only 38% (8 of 21) showed evidence of ERK activation. Kinase assays revealed that 77% of brain tumor cell lines activated JNK in response to EGF (7 of 13) or had high levels of basal activity (3 of 13), whereas none of six normal cell lines analysed, including astrocytes, had these properties. Of several growth factors examined, EGF produced the highest level of JNK induction in tumor cell lines and the duration of activation was greater than that seen for ERK. Expression of a dominant-negative (dn) form of JNK potently inhibited EGF mediated anchorage independent growth and protection from cell death in two glial tumor cell lines. These findings demonstrate that enhanced JNK activation is frequently found in primary brain tumors and that this activation contributes to phenotypes related to transformation.

[1]  M. Antonyak,et al.  Constitutive Activation of c-Jun N-terminal Kinase by a Mutant Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.

[2]  O. Potapova,et al.  The Jun Kinase/Stress-activated Protein Kinase Pathway Functions to Regulate DNA Repair and Inhibition of the Pathway Sensitizes Tumor Cells to Cisplatin* , 1997, The Journal of Biological Chemistry.

[3]  T. Hambuch,et al.  The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Schlessinger,et al.  Activation of the JNK pathway is essential for transformation by the Met oncogene , 1997, The EMBO journal.

[5]  Stuart K. Kim,et al.  Signaling specificity: the RTK/RAS/MAP kinase pathway in metazoans. , 1999, Trends in genetics : TIG.

[6]  M. Karin,et al.  Selective activation of the JNK signaling cascadeand c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs , 1995, Cell.

[7]  M. Shibuya,et al.  Shc Regulates Epidermal Growth Factor-induced Activation of the JNK Signaling Pathway* , 1999, The Journal of Biological Chemistry.

[8]  R. Davis,et al.  The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. , 1996, The Journal of biological chemistry.

[9]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[10]  P. Crespo,et al.  The small GTP-binding proteins Rac1 and Cdc42regulate the activity of the JNK/SAPK signaling pathway , 1995, Cell.

[11]  G. Nuovo,et al.  Hyperexpression of mitogen-activated protein kinase in human breast cancer. , 1997, The Journal of clinical investigation.

[12]  J. Schlessinger,et al.  Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway , 1997, Molecular and cellular biology.

[13]  J. Woodgett,et al.  The stress-activated protein kinase subfamily of c-Jun kinases , 1994, Nature.

[14]  M. Karin,et al.  c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases , 1994, Molecular and cellular biology.

[15]  L. Mucke,et al.  Dynamic regulation of c-Jun N-terminal kinase activity in mouse brain by environmental stimuli. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[17]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[18]  N. Holbrook,et al.  Protective Role for c-Jun in the Cellular Response to DNA Damage* , 2001, The Journal of Biological Chemistry.

[19]  F. McCormick,et al.  Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation , 1997, Molecular and cellular biology.

[20]  M. T. Abreu-Martin,et al.  Mitogen-Activated Protein Kinase Kinase Kinase 1 Activates Androgen Receptor-Dependent Transcription and Apoptosis in Prostate Cancer , 1999, Molecular and Cellular Biology.

[21]  C. Damsky,et al.  Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. , 2000 .

[22]  D. Mercola,et al.  The JUN Kinase/Stress-activated Protein Kinase Pathway Is Required for Epidermal Growth Factor Stimulation of Growth of Human A549 Lung Carcinoma Cells* , 1997, The Journal of Biological Chemistry.

[23]  M. Karin,et al.  JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain , 1994, Cell.

[24]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[25]  H. Saya,et al.  Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway , 2001, The Journal of cell biology.

[26]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[27]  P. Zoltick,et al.  The molecular biology and molecular genetics of astrocytic neoplasms. , 1994, Seminars in oncology.

[28]  David L. Brautigan,et al.  Raf-1 activates MAP kinase-kinase , 1992, Nature.

[29]  G L Johnson,et al.  Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. , 1994, Science.

[30]  K. Rodland,et al.  Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. , 1999, Experimental cell research.

[31]  M. Gorospe,et al.  Inhibition of c-Jun N-Terminal Kinase 2 Expression Suppresses Growth and Induces Apoptosis of Human Tumor Cells in a p53-Dependent Manner , 2000, Molecular and Cellular Biology.

[32]  M. Karin,et al.  Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73 , 1991, Nature.

[33]  W. Imagawa,et al.  Altered MAP kinase (ERK1,2) regulation in primary cultures of mammary tumor cells: elevated basal activity and sustained response to EGF. , 1999, Carcinogenesis.

[34]  A. Ashworth,et al.  An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1 , 1995, Science.

[35]  R. Davis,et al.  Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways , 1996, Journal of Molecular Medicine.

[36]  S. Vandenberg,et al.  In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. , 1998, The American journal of pathology.

[37]  N. Ahn,et al.  Transformation of mammalian cells by constitutively active MAP kinase kinase. , 1994, Science.

[38]  O. Potapova,et al.  The Jun Kinase 2 Isoform Is Preferentially Required for Epidermal Growth Factor-Induced Transformation of Human A549 Lung Carcinoma Cells , 1999, Molecular and Cellular Biology.